-
Kenya's economy faces climate change risks: World Bank
-
In crisis-hit Cuba, World Cup offers brief respite
-
UK intercepts Russian shadow fleet vessel in Channel
-
London, Tokyo agree $24-bn investment deal
-
Indonesian economy comes up for air but struggles to win back investors
-
Trump says US-Iran deal to be signed Sunday, Hormuz to open after
-
Between Trump and a hard place: Fed chair Warsh to lead first rate meeting
-
High-school drop out to big time crime boss, Venezuela's 'Nino Guerrero'
-
US-Iran deal could be finalised soon, mediator Pakistan says
-
Thousands gather in Thai capital to mourn late princess
-
US says downed multiple Iran drones as both insist deal closer
-
SpaceX: Five key moments, from first launch to Starship megarocket
-
US clears Paramount's $111 bn Warner Bros. takeover
-
Iran and US say deal closer than ever
-
Cuba opens more sectors to private business
-
World Cup struggles to ignite US excitement
-
US appellate court upholds Sam Bankman-Fried criminal sentence
-
France bids farewell to girl, 11, whose killing sparked outrage
-
Wall Street wobbles as SpaceX shares launch, oil slides on Mideast deal hopes
-
SpaceX lifts off in record Wall Street debut
-
US deportation flight carrying Iranians en route to C.African Republic
-
At a Libyan university once ravaged by war, students dream again
-
Kenya mourns schoolgirls killed in suspected dorm arson attack
-
Stocks rally, oil slides on Mideast deal hopes
-
'All of us of are migrants,' pope says in Canary Islands
-
Switzerland split on immigration vote: four perspectives
-
Thai princess dies aged 47 after three years in hospital
-
Science fiction? Musk's lofty SpaceX goals unrealistic, skeptics say
-
Asia stocks up, oil down on Mideast deal hopes
-
From cage fights to the White House, UFC marches into mainstream
-
Pope ends Spain visit with migrant meetings
-
Ex-Tottenham owner sells art collection in blockbuster auction
-
Antarctic Peninsula sees record high June temperatures
-
US stocks rally, oil prices fall as Trump calls off fresh Iran strikes
-
SpaceX to make historic IPO that could make Musk a trillionaire
-
El Nino is back, but its effects vary widely
-
First leather bag from T-Rex cells to be auctioned in Paris
-
Four times as many icebergs calved from Greenland glaciers: study
-
Stocks rebound, oil wavers as traders weigh Iran, rates outlook
-
Niger criminalises same-sex relations with jail terms
-
Smuggled dinosaur fossils return to Mongolia after two decades
-
Over 260 Nigerians fleeing xenophobic attacks in S. Africa return home
-
Pope condemns 'indifference' towards migrants on Canaries trip
-
Sweden withdraws controversial proposal to jail 13-year-olds
-
Economic pressures 'manageable': Indonesian deputy finance minister
-
Scientists warn of record heat, threats to climate monitoring
-
Sweden withdraws disputed proposal to jail 13-year-olds
-
UK probes Ryanair over fees for parents to sit with children
-
Suspense surrounds Swiss anti-immigration vote
-
Rising costs and competition threaten GoPro
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
P.Petrenko--CPN